While the pace of global biosimilar adoption has been uneven, the opening of the U.S. market marks a major turning point. Global sales are expected to grow to $35B by 2020 (from only $1.3B in 2013) as more than $69B of biologics go off patent by 2018.

For a closer look at global biosimilar markets, read The Bullish Outlook for Biosimilars, recently authored by Numerof experts and published by BioPharm International.  The article highlights key patent expiries, recent regulations, adoption trends, challenges facing both biosimilar and originator manufacturers, and strategies for long-term success.